Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Lidocaine and Methionine

supplement:

Methionine

Research Papers that Mention the Interaction

Lidocaine (10 microM) effectively reduced the peak Na currents in M myocytes, but had little affect on the current-voltage curve in N myocytes.
Journal of the Formosan Medical Association = Taiwan yi zhi  •  1993  |  View Paper
2 Amlodipine (0.5–2 × 10−4 M), … M), diltiazem (1–8 × 10−4 M), lignocaine (0.1–2 × 10−3 M) and cobalt (2–… order of potency, but not nifedipine (1–5 × 10−3 M ), increased the latency and inhibited, then abolished, … potentials in a concentration‐dependent manner.
British journal of pharmacology  •  1986  |  View Paper
This plateau value j infinity min, 0.9 +/- 0.09 M +/- S.E.M.) in control conditions, was decreased by lidocaine in a dose-dependent way with a Km of 388 microM. The time constant of the recovery from slow inactivation was significantly reduced by lidocaine.
The Journal of pharmacology and experimental therapeutics  •  1982  |  View Paper
Lidocaine and tetracaine also inhibited radioligand binding to … K 1 values of 5.25 × 10 −4 M and 4.85 × 10 −5 M for the α-receptor and 8.2 × 10 t-5 … 6.94 × 10 −6 M for the muscarinic receptor; these inhibitions also appeared to be competitive.
Biochemical pharmacology  •  1980  |  View Paper
lidocaine and MEGX was not reversed by excess calcium, 2.2 and 4.4 mM, … cocaine, 3 × 10−6 M. Lidocaine, 5 × 10−4 M, and MEGX, 2 × 10−3 M , shifted the dose–response curve of NE to the … × 10−4 M, shifted the curve to the left.
Anesthesiology  •  1980  |  View Paper
Lidocaine at 4.0 × 10-5 M produced a marked shortening of the APD in the entire voltage range.
Journal of cardiovascular pharmacology and therapeutics  •  1997  |  View Paper